Kenneth H. Mayer, MD

Medical Research Director
Fenway Health

Disclosure(s): Gilead: Advisor/Consultant; Merck: Advisor/Consultant; ViiV: Advisor/Consultant

Poster(s):

• 1277 - Provider Perspectives on Long-Acting Injectable Antiretroviral Therapy: A “Golden Ticket”?
  Friday, October 21, 2022

  12:15 PM – 1:30 PM US ET

• 2087 - Prescription Adherence and Persistence on Oral Pre-exposure Prophylaxis (PrEP) Among PrEP-Naive (PN) Individuals After F/TAF Approval in the United States (US)
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET